Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302

BACKGROUND: Treatment patterns for metastatic castration-resistant prostate cancer (mCRPC) have changed substantially in the last few years. In trial COU-AA-302 (chemotherapy-naïve men with mCRPC), abiraterone acetate plus prednisone (AA) significantly improved radiographic progression-free survival...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Eur Urol
Главные авторы: de Bono, Johann S., Smith, Matthew R., Saad, Fred, Rathkopf, Dana E., Mulders, Peter F.A., Small, Eric J., Shore, Neal D., Fizazi, Karim, De Porre, Peter, Kheoh, Thian, Li, Jinhui, Todd, Mary B., Ryan, Charles J., Flaig, Thomas W.
Формат: Artigo
Язык:Inglês
Опубликовано: 2016
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5609503/
https://ncbi.nlm.nih.gov/pubmed/27402060
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eururo.2016.06.033
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы